Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Berlin - Delayed Quote EUR

Inventiva SA (6IV.BE)

Compare
2.8550
+0.0500
+(1.78%)
At close: April 17 at 7:33:02 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 6IV.BE

Recent News: 6IV.BE

View More
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
GlobeNewswire 4 days ago
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?

Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?
Zacks 15 days ago
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
GlobeNewswire 18 days ago
Inventiva SA (IVEVF) (Q4 2024) Earnings Call Highlights: Navigating Financial Challenges and ...

Inventiva SA (IVEVF) (Q4 2024) Earnings Call Highlights: Navigating Financial Challenges and ...
GuruFocus.com 22 days ago
Inventiva reports its 2024 full year results and provides a business update

Inventiva reports its 2024 full year results and provides a business update
GlobeNewswire 24 days ago
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
GlobeNewswire last month
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
GlobeNewswire last month
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
GlobeNewswire last month
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
GlobeNewswire 2 months ago
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
GlobeNewswire 2 months ago
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
GlobeNewswire 2 months ago
View More

Related Tickers

4RD.DU Maat Pharma SA
5.96
+2.41%
 
TGNA.BE Transgene SA
0.5920
-1.33%
 
MDCLF MedinCell S.A.
6.98
0.00%
 
SIGHT.PA GenSight Biologics S.A.
0.2265
-1.95%
 
GNFT.PA Genfit S.A.
3.0700
-1.98%
 
VLA.PA Valneva SE
3.0360
+1.13%